Literature DB >> 21678334

Interventions for primary vesicoureteric reflux.

Evi Vt Nagler1, Gabrielle Williams, Elisabeth M Hodson, Jonathan C Craig.   

Abstract

BACKGROUND: Vesicoureteric reflux (VUR) results in urine passing retrograde up the ureter. Urinary tract infections (UTI) associated with VUR have been considered a cause of permanent renal parenchymal damage in children with VUR. Management of these children has been directed at preventing UTI by antibiotic prophylaxis and/or surgical correction of VUR. The optimum strategy is not clear.
OBJECTIVES: To evaluate the benefits and harms of different treatment options for primary VUR. SEARCH STRATEGY: In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened reference lists of papers and abstracts from conference proceedings. SELECTION CRITERIA: RCTs in any language comparing any treatment of VUR including surgical or endoscopic correction, antibiotic prophylaxis, non-invasive non-pharmacological techniques and any combination of therapies. DATA COLLECTION AND ANALYSIS: Two authors independently searched the literature, determined study eligibility, assessed quality, extracted and entered data. We expressed dichotomous outcomes as risk ratios (RR) and their 95% confidence intervals (CI) and continuous data as mean differences (MD) and their 95% CI's Data were pooled using the random effects model. MAIN
RESULTS: Twenty RCTs (2324 children) were included. Long-term low-dose antibiotic prophylaxis compared to no treatment/placebo did not significantly reduce repeat symptomatic UTI (846 children: RR 0.68, 95% CI 0.39 to 1.17) or febrile UTI (946 children: RR 0.77, 95% CI 0.47 to 1.24) at two years. There was considerable heterogeneity in the analyses and only one study was adequately blinded. At one to three years, antibiotic prophylaxis reduced the risk of new or progressive renal damage on DMSA scan (446 children: RR 0.35, 95% CI 0.15 to 0.80). Side effects were infrequent when reported, but antibiotics increased the likelihood of bacterial drug resistance threefold (132 UTIs: RR 2.94, 95% CI 1.39 to 6.25).When long-term antibiotic prophylaxis was compared with surgical or endoscopic correction of VUR plus antibiotics for one to 24 months (10 studies, 1141 children), the risk of symptomatic UTI was not significantly different at any time point. Combined surgical and antibiotic treatment caused a 57% reduction in febrile UTI by five years (2 studies, 449 children: RR 0.43, 95% CI 0.27 to 0.70) but did not decrease the risk of new or progressive renal damage at any time point. Postoperative obstruction was seen in 0% and 7% of children in two surgical studies and 0% in one endoscopic study. AUTHORS'
CONCLUSIONS: Compared with no treatment, use of long-term, low-dose antibiotics did not significantly reduce the number of repeat symptomatic and febrile UTIs in children with VUR. Considerable heterogeneity in the analyses and inclusion of only one adequately blinded study, made drawing firm conclusions challenging. Antibiotic prophylaxis significantly reduced the risk of developing new or progressive renal damage, but assuming an 8% baseline risk, 33 children would need long-term antibiotic prophylaxis to prevent one more child developing kidney damage over the course of two to three years.The added benefit of surgical or endoscopic correction of VUR over antibiotic treatment alone remains unclear. Eight children would require combined surgical and antibiotic treatment to prevent one additional child developing febrile UTI by five years, but it would not cause fewer children developing renal damage.

Entities:  

Mesh:

Year:  2011        PMID: 21678334     DOI: 10.1002/14651858.CD001532.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  24 in total

1.  Antibiotic prophylaxis in vesicoureteral reflux: A practice revisited.

Authors:  Jessica Robinson
Journal:  Can Pharm J (Ott)       Date:  2013-03

2.  Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis.

Authors:  Rachel E Selekman; Daniel J Shapiro; John Boscardin; Gabrielle Williams; Jonathan C Craig; Per Brandström; Marco Pennesi; Gwenalle Roussey-Kesler; Pankaj Hari; Hillary L Copp
Journal:  Pediatrics       Date:  2018-07       Impact factor: 7.124

3.  Probiotics prophylaxis in pyelonephritis infants with normal urinary tracts.

Authors:  Seung Joo Lee; Jihae Cha; Jung Won Lee
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

Review 4.  Genetics of vesicoureteral reflux.

Authors:  Prem Puri; Jan-Hendrik Gosemann; John Darlow; David E Barton
Journal:  Nat Rev Urol       Date:  2011-08-23       Impact factor: 14.432

5.  Should simultaneous ureteral reimplantation be performed during sigmoid bladder augmentation to reduce vesicoureteral reflux in neurogenic bladder cases?

Authors:  Peng Zhang; Yong Yang; Zhi-jin Wu; Ning Zhang; Chao-hua Zhang; Xiao-dong Zhang
Journal:  Int Urol Nephrol       Date:  2015-03-31       Impact factor: 2.370

6.  Parental Preference Assessment for Vesicoureteral Reflux Management in Children.

Authors:  Geraldine N Tran; Anand V Bodapati; Jonathan C Routh; Christopher S Saigal; Hillary L Copp
Journal:  J Urol       Date:  2016-12-11       Impact factor: 7.450

Review 7.  The pathogenesis and management of renal scarring in children with vesicoureteric reflux and pyelonephritis.

Authors:  Vasikar Murugapoopathy; Christine McCusker; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2019-03-07       Impact factor: 3.714

Review 8.  To screen or not to screen for vesicoureteral reflux in children with ureteropelvic junction obstruction: a systematic review.

Authors:  Marcus Weitz; Maria Schmidt
Journal:  Eur J Pediatr       Date:  2016-11-25       Impact factor: 3.183

9.  A single-center cohort of Canadian children with VUR reveals renal phenotypes important for genetic studies.

Authors:  Jasmine El Andalousi; Inga J Murawski; John-Paul Capolicchio; Mohamed El-Sherbiny; Roman Jednak; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2013-03-26       Impact factor: 3.714

10.  Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial.

Authors:  Pankaj Hari; Smriti Hari; Aditi Sinha; Rakesh Kumar; Arti Kapil; Ravindra Mohan Pandey; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2014-08-31       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.